h1

% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@PHDTHESIS{Cromme:834834,
      author       = {Cromme, Tina Andrea},
      othercontributors = {Brehmer, Bernhard and Spillner, Jan},
      title        = {{D}ie {S}equenztherapie beim metastasierten
                      {N}ierenzellkarzinom : {A}uswertung des
                      {P}atientenkollektivs am {UK} {A}achen bis {O}ktober 2011,
                      eingebettet in eine {M}etaanalyse relevanter {A}rbeiten zu
                      den {S}equenzierungen {S}orafenib-{S}unitinib und
                      {S}unitinib-{S}orafenib},
      school       = {Rheinisch-Westfälische Technische Hochschule Aachen},
      type         = {Dissertation},
      address      = {Aachen},
      reportid     = {RWTH-2021-10174},
      pages        = {97 Seiten : Diagramme},
      year         = {2021},
      note         = {Dissertation, Rheinisch-Westfälische Technische Hochschule
                      Aachen, 2021},
      abstract     = {Since targeted agents were first launched in 2005 the
                      prognosis for patients with metastatic renal cell carcinoma
                      improved significantly. In the past many questions
                      concerning the most beneficial sequencing of the different
                      agents arose, were partly answered, partly dismissed and
                      partly remain to be answered by strong data. For the present
                      study, the data of 20 patients who were treated with the
                      sequence Sunitinib-Sorafenib at Aachen University hospital
                      until October 2011 were retrospectively captured and
                      analyzed. Subsequently the results were put into perspective
                      and compared to similar studies identified on Pubmed. In the
                      present study, the median time to progression under
                      Sunitinib was 12.7 months and the median time to progression
                      under Sorafenib 5.5 month. The time to second progression
                      from the start of the first agent until progress/censoring
                      on the second was 21.7 months. The longest combined
                      progression free survival for the reciprocal sequence in
                      compared studies was 18.2 months. The results of the present
                      study compared to published data suggest that there is no
                      advantage to either sequence for the whole collective of
                      patients. Nevertheless, for the subgroup of patients older
                      than 65 years of age, the present data shows a significant
                      lesser value in comparison to the whole collective for the
                      sequence applied. This supports the results of the subgroup
                      analysis of the SWITCH-study which found a possible
                      superiority of the sequence Sorafenib-Sunitinib for patients
                      older than 65. Moreover, the results of the present study
                      support the hypothesis that TSH could be used as a
                      predictive biomarker in order to evaluate a response to
                      therapy. $61.5\%$ of the patients who responded to Sunitinib
                      showed an elevation of TSH while receiving the agent. The
                      results of the present study should be validated by further
                      prospective studies including larger cohorts of patients.},
      cin          = {533700-2},
      ddc          = {610},
      cid          = {$I:(DE-82)533700-2_20140620$},
      typ          = {PUB:(DE-HGF)11},
      url          = {https://publications.rwth-aachen.de/record/834834},
}